Abstract
Recent advances in research on depression have confirmed that it is common, recurrent and disabling mental disorder. Current medication for the treatment of depression have limited efficacy and delayed onset of therapeutic action. In view of the limitation of the current antidepressant pharmaceuticals, tremendous research efforts are ongoing to search for a pharmacological treatment which may improve antidepressive efficacy, onset of action or even both therapeutic parameters. To address these needs, numerous combination therapies that maintain the benefits associated with selective serotonin reuptake inhibitors (SSRIs) but attempts to improve efficacy or reduce side effects by additional mechanism (5-HT1A, 5-HT2C ) and newer approaches targeting excitatory (glutamate, NMDA,mGluR2, mGluR5) or inhibitory aminoacid system (GABA) or peptidergic system(neurokinin1, corticotrophin releasing factor1, melanin concentrating hormone1) have been identified. The goal of this review is to give a brief overview of the major advances in monoamine based treatment strategies and the new emerging approaches in the treatment of depression.
Keywords: Depression, SSRIs, GABA, monoamine, glutamate, serotonin
Current Pharmaceutical Design
Title: Antidepressants: Current Strategies and Future Opportunities
Volume: 16 Issue: 38
Author(s): Archana Uppal, Anita Singh, Prashant Gahtori, Surajit Kumar Ghosh and Mohammad Zaki Ahmad
Affiliation:
Keywords: Depression, SSRIs, GABA, monoamine, glutamate, serotonin
Abstract: Recent advances in research on depression have confirmed that it is common, recurrent and disabling mental disorder. Current medication for the treatment of depression have limited efficacy and delayed onset of therapeutic action. In view of the limitation of the current antidepressant pharmaceuticals, tremendous research efforts are ongoing to search for a pharmacological treatment which may improve antidepressive efficacy, onset of action or even both therapeutic parameters. To address these needs, numerous combination therapies that maintain the benefits associated with selective serotonin reuptake inhibitors (SSRIs) but attempts to improve efficacy or reduce side effects by additional mechanism (5-HT1A, 5-HT2C ) and newer approaches targeting excitatory (glutamate, NMDA,mGluR2, mGluR5) or inhibitory aminoacid system (GABA) or peptidergic system(neurokinin1, corticotrophin releasing factor1, melanin concentrating hormone1) have been identified. The goal of this review is to give a brief overview of the major advances in monoamine based treatment strategies and the new emerging approaches in the treatment of depression.
Export Options
About this article
Cite this article as:
Uppal Archana, Singh Anita, Gahtori Prashant, Kumar Ghosh Surajit and Zaki Ahmad Mohammad, Antidepressants: Current Strategies and Future Opportunities, Current Pharmaceutical Design 2010; 16 (38) . https://dx.doi.org/10.2174/138161210794519110
DOI https://dx.doi.org/10.2174/138161210794519110 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Proteins - Two Sides of a Coin
Current Cardiology Reviews Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication
Current Pharmaceutical Design Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Management of Idiopathic Intracranial Hypertension During the COVID-19 Pandemic
Reviews on Recent Clinical Trials Design and Synthesis of Mannich bases as Benzimidazole Derivatives as Analgesic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Modulation of Individual Susceptibility to the No-Reflow Phenomenon after Acute Myocardial Infarction
Current Pharmaceutical Design Most Efficient Routes for the Synthesis of α,β-Diamino Acid-Derived Compounds
Current Pharmaceutical Design Hybrid Stress Testing by Adenosine Infusion and Exercise Myocardial Perfusion Imaging: A Critical Appraisal
Current Cardiology Reviews Yielding Criterion of Porcine Thoracic Aorta
Recent Patents on Cardiovascular Drug Discovery Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms
Current Vascular Pharmacology Serum Vitamin D Concentration and Potential Risk Factors for its Deficiency in HIV Positive Individuals
Current HIV Research Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Ketamine: New Indications for an Old Drug
Current Drug Targets A Review of Hypertension Management in Atrial Fibrillation
Current Hypertension Reviews Editorial [Hot Topic:Stabilizing the Vulnerable Plaque: The Search for the Magic Bullet (Executive Editors: G. Pasterkamp and M. Daemen)]
Current Pharmaceutical Design Diet and Metabolic Syndrome: An Overview
Current Vascular Pharmacology Cell Adhesion Molecules and Cadmium
Current Chemical Biology Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Current Drug Targets Clinical Significance of the Blood Pressure Changes from Day to Night
Current Hypertension Reviews